Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
A Study of Emi-Le in Participants with Solid Tumors
Recurrent or advanced solid tumor and has disease [+5]
Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin p... [+8]
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participants will be administered DAY301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD); In Phase 1b dose expansion, DAY301 will be evaluated in dose expansion cohorts.
Ovarian cancer [+12]
Prior use of PTK7 targeting treatment (Phase 1a) or prior use of PTK7 targeting... [+8]
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.
Low Grade Glioma & Low-Grade Glioma Extension: a relapsed or progressive LGG wit... [+4]
Participant's tumor has additional previously-known activating molecular alterat... [+2]